Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Accelerate Diagnostics Inc is a diagnostics & research business based in the US. Accelerate Diagnostics shares (AXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Accelerate Diagnostics employs 224 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.38|
|52-week range||$5.15 - $15.60|
|50-day moving average||$5.94|
|200-day moving average||$7.14|
|Wall St. target price||$12.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-1.24%|
|1 month (2021-09-20)||6.87%|
|3 months (2021-07-20)||-7.00%|
|6 months (2021-04-20)||-18.62%|
|1 year (2020-10-20)||-42.57%|
|2 years (2019-10-18)||-63.52%|
|3 years (2018-10-19)||16.73|
|5 years (2016-10-20)||23.25|
|Revenue TTM||$12 million|
|Gross profit TTM||$4.5 million|
|Return on assets TTM||-40.39%|
|Return on equity TTM||0%|
|Market capitalisation||$442.7 million|
TTM: trailing 12 months
There are currently 7.5 million Accelerate Diagnostics shares held short by investors – that's known as Accelerate Diagnostics's "short interest". This figure is 3.3% down from 7.7 million last month.
There are a few different ways that this level of interest in shorting Accelerate Diagnostics shares can be evaluated.
Accelerate Diagnostics's "short interest ratio" (SIR) is the quantity of Accelerate Diagnostics shares currently shorted divided by the average quantity of Accelerate Diagnostics shares traded daily (recently around 244087.49181401). Accelerate Diagnostics's SIR currently stands at 30.54. In other words for every 100,000 Accelerate Diagnostics shares traded daily on the market, roughly 30540 shares are currently held short.
However Accelerate Diagnostics's short interest can also be evaluated against the total number of Accelerate Diagnostics shares, or, against the total number of tradable Accelerate Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Accelerate Diagnostics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Accelerate Diagnostics shares in existence, roughly 110 shares are currently held short) or 0.2197% of the tradable shares (for every 100,000 tradable Accelerate Diagnostics shares, roughly 220 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Accelerate Diagnostics.
Find out more about how you can short Accelerate Diagnostics stock.
We're not expecting Accelerate Diagnostics to pay a dividend over the next 12 months.
Accelerate Diagnostics's shares were split on a 1231:1230 basis on 7 July 2013. So if you had owned 1230 shares the day before before the split, the next day you'd have owned 1231 shares. This wouldn't directly have changed the overall worth of your Accelerate Diagnostics shares – just the quantity. However, indirectly, the new 0.1% lower share price could have impacted the market appetite for Accelerate Diagnostics shares which in turn could have impacted Accelerate Diagnostics's share price.
Over the last 12 months, Accelerate Diagnostics's shares have ranged in value from as little as $5.15 up to $15.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Accelerate Diagnostics's is 1.881. This would suggest that Accelerate Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Accelerate Diagnostics, Inc. , an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.